Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond.
Saved in:
| Title: | Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. |
|---|---|
| Authors: | Lattanzi, Simona (AUTHOR), Chiesa, Valentina (AUTHOR), Di Gennaro, Giancarlo (AUTHOR), Ferlazzo, Edoardo (AUTHOR), Labate, Angelo (AUTHOR), La Neve, Angela (AUTHOR), Meletti, Stefano (AUTHOR), Di Bonaventura, Carlo (AUTHOR), Audenino, Daniela (AUTHOR), Boero, Giovanni (AUTHOR), Cianci, Vittoria (AUTHOR), Coletti Moja, Mario (AUTHOR), Cumbo, Eduardo (AUTHOR), Dainese, Filippo (AUTHOR), Didato, Giuseppe (AUTHOR), Fallica, Elisa (AUTHOR), Giordano, Alfonso (AUTHOR), Le Piane, Emilio (AUTHOR), Panebianco, Mariangela (AUTHOR), Piccioli, Marta (AUTHOR) |
| Source: | Neurological Sciences. Sep2024, Vol. 45 Issue 9, p4519-4527. 9p. |
| Subjects: | Delphi method, Partial epilepsy, People with epilepsy, Older patients, Epilepsy |
| Abstract: | Background: Antiseizure medications remain the cornerstone of treatment for epilepsy, although a proportion of individuals with the condition will continue to experience seizures despite appropriate therapy. Treatment choices for epilepsy are based on variables related to both the individual patient and the available medications. Brivaracetam is a third-generation agent antiseizure medication. Methods: We carried out a Delphi consensus exercise to define the role of brivaracetam in clinical practice and to provide guidance about its use as first add-on ASM and in selected clinical scenarios. A total of 15 consensus statements were drafted by an expert panel following review of the literature and all were approved in the first round of voting by panelists. The consensus indicated different clinical scenarios for which brivaracetam can be a good candidate for treatment, including first add-on use. Results: Overall, brivaracetam was considered to have many advantageous characteristics that render it a suitable option for patients with focal epilepsy, including a fast onset of action, favorable pharmacokinetic profile with few drug-drug interactions, broad-spectrum activity, and being well tolerated across a range of doses. Brivaracetam is also associated with sustained clinical response and good tolerability in the long term. Conclusions: These characteristics also make it suitable as an early add-on for the elderly and for patients with post-stroke epilepsy or status epilepticus as highlighted by the present Delphi consensus. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Antiseizure medications remain the cornerstone of treatment for epilepsy, although a proportion of individuals with the condition will continue to experience seizures despite appropriate therapy. Treatment choices for epilepsy are based on variables related to both the individual patient and the available medications. Brivaracetam is a third-generation agent antiseizure medication. Methods: We carried out a Delphi consensus exercise to define the role of brivaracetam in clinical practice and to provide guidance about its use as first add-on ASM and in selected clinical scenarios. A total of 15 consensus statements were drafted by an expert panel following review of the literature and all were approved in the first round of voting by panelists. The consensus indicated different clinical scenarios for which brivaracetam can be a good candidate for treatment, including first add-on use. Results: Overall, brivaracetam was considered to have many advantageous characteristics that render it a suitable option for patients with focal epilepsy, including a fast onset of action, favorable pharmacokinetic profile with few drug-drug interactions, broad-spectrum activity, and being well tolerated across a range of doses. Brivaracetam is also associated with sustained clinical response and good tolerability in the long term. Conclusions: These characteristics also make it suitable as an early add-on for the elderly and for patients with post-stroke epilepsy or status epilepticus as highlighted by the present Delphi consensus. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-024-07485-w |
